COVIDOCS: Impact of COVID-19 on Mental Health of OCD Patients and live-in Family Members

Sponsor
University Hospital, Ghent (Other)
Overall Status
Completed
CT.gov ID
NCT05656456
Collaborator
(none)
75
1
7.6
9.9

Study Details

Study Description

Brief Summary

The impact of the current Covid-19 pandemic on mental health of people with preexisting psychiatric problems is enormous. This longitudinal study investigates the prevalence of mental health problems (obsessive compulsive, or depressive symptoms, anxiety, stress...) of obsessive-compulsive disorder (OCD) patients and their live-in family members. We also aim to investigate the impact of the pandemic, isolation measures, exposure to media and changing therapeutic setting in OCD patients and their live-in family members through qualitative research.

Condition or Disease Intervention/Treatment Phase
  • Other: Y-BOCS or FAS online survey, interview

Detailed Description

The impact of the current Covid-19 pandemic on mental health of people with preexisting psychiatric problems is enormous. Previous studies during the SARS outbreak demonstrated a significant burden and increase of mental health problems in people with preexisting psychiatric problems, but little is known about the impact on preexisting obsessive-compulsive disorder (OCD). This longitudinal study aims to investigate the prevalence of mental health problems of OCD patients during and after the Covid-19 pandemic. We also want to investigate the impact on family accommodation (FA). There is growing evidence that FA maintains and/or facilitates OCD symptoms. OCD patients and their live-in family members, followed at the Centre for OCD of the Ghent university hospital, will be included. Sociodemographic data, data regarding employment and previous mental health problems will be collected at the first survey. The Y-BOCS (OCD symtoms) and FAS (family accommodation) will be taken from patients and family members respectively at the start, after 1, 3 and 6 months. The Depression, Anxiety and Stress Scale (DASS-21), the Dutch translation of the Covid-19 Peritraumatic Distress Index (CPDI) will be administered at the same time points through an online survey.

Secondly, patients and live-in family members will be interviewed about their experiences concerning the covid pandemic, the isolation measures, media exposure and change of mental health practice and the impact on the OCD (qualitative research).

Study Design

Study Type:
Observational
Actual Enrollment :
75 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Impact of the COVID-19 Pandemic on Patients With Obsessive-Compulsive Disorder and Their live-in Family Members
Actual Study Start Date :
Apr 6, 2020
Actual Primary Completion Date :
Nov 22, 2020
Actual Study Completion Date :
Nov 22, 2020

Arms and Interventions

Arm Intervention/Treatment
OCD patients

Patients with obsessive-compulsive disorder

Other: Y-BOCS or FAS online survey, interview
Y-BOCS or FAS and online survey will be administered interview will be conducted

live-in family members

Live-in family members of OCD patients

Other: Y-BOCS or FAS online survey, interview
Y-BOCS or FAS and online survey will be administered interview will be conducted

Outcome Measures

Primary Outcome Measures

  1. OCD symptoms in patients at baseline [Baseline]

    OCD symptoms as measured by the Y-BOCS

  2. Family accommodation in family members at baseline [Baseline]

    FA as measured by the family accommodation scale (FAS)

  3. Change in OCD symptoms in patients [Baseline + 30 days, baseline + 90 days, baseline + 180 days]

    OCD symptoms as measured by the Y-BOCS

  4. Change in family accommodation in family members [Baseline + 30 days, baseline + 90 days, baseline + 180 days]

    FA as measured by the family accommodation scale (FAS)

Secondary Outcome Measures

  1. Depressive symptoms at baseline in patients and family members [Baseline]

    Depressive symptoms as measured by the 7-item depression subscale of the self-reported 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21-Depression). A higher score indicates more depressive symptoms with a minimum score of 0 and a maximum score of 21.

  2. Change in depressive symptoms in patients and family members [Baseline + 30 days, baseline + 90 days, baseline + 180 days]

    Depressive symptoms as measured by the 7-item depression subscale of the self-reported 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21-Depression). A higher score indicates more depressive symptoms with a minimum score of 0 and a maximum score of 21.

  3. Anxiety symptoms at baseline in patients and family members [Baseline]

    Anxiety symptoms as measured by the 7-item depression subscale of the self-reported 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21-Depression). A higher score indicates more anxiety symptoms with a minimum score of 0 and a maximum score of 21.

  4. Change in anxiety symptoms in patients and family members [Baseline + 30 days, baseline + 90 days, baseline + 180 days]

    Anxiety symptoms as measured by the 7-item depression subscale of the self-reported 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21-Depression). A higher score indicates more anxiety symptoms with a minimum score of 0 and a maximum score of 21.

  5. Stress levels at baseline in patients and family members [Baseline]

    Stress as measured by the 7-item depression subscale of the self-reported 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21-Depression). A higher score indicates more stress levels with a minimum score of 0 and a maximum score of 21.

  6. Change in stress levels in patients and family members [Baseline + 30 days, baseline + 90 days, baseline + 180 days]

    Stress as measured by the 7-item depression subscale of the self-reported 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21-Depression). A higher score indicates more stress levels with a minimum score of 0 and a maximum score of 21.

  7. Covid-19 related psychological stress at baseline in patients and family members [Baseline]

    Specific distress regarding Covid-19 will be measured by the Dutch translation of the COVID-19 Peritraumatic Distress Index (CPDI). This self-reported questionnaire inquires about the frequency of anxiety, depression, specific phobias, cognitive change, avoidance and compulsive behaviour, physical symptoms and loss of social functioning in the past week. The score ranges from 0 to 100, with higher scores indicating more distress.

  8. Change in Covid-19 related psychological stress in patients and family members [Baseline + 30 days, baseline + 90 days, baseline + 180 days]

    Specific distress regarding Covid-19 will be measured by the Dutch translation of the COVID-19 Peritraumatic Distress Index (CPDI). This self-reported questionnaire inquires about the frequency of anxiety, depression, specific phobias, cognitive change, avoidance and compulsive behaviour, physical symptoms and loss of social functioning in the past week. The score ranges from 0 to 100, with higher scores indicating more distress.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • OCD patients

  • live-in family members of OCD patients

Exclusion Criteria:
  • not speaking fluently Dutch

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ghent University Hospital Ghent Belgium 9000

Sponsors and Collaborators

  • University Hospital, Ghent

Investigators

  • Study Director: Gilbert MD Lemmens, MD, PhD, University Hospital, Ghent

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Ghent
ClinicalTrials.gov Identifier:
NCT05656456
Other Study ID Numbers:
  • BC-07561
First Posted:
Dec 19, 2022
Last Update Posted:
Dec 19, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Ghent
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 19, 2022